Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Competing Endogenous LncRNA 3 for miR-645 (CERNA3)
- Target
- CERNA3
- Molecular classification
- Long non-coding RNA (lncRNA), Competing endogenous RNA (ceRNA)
01
Overview
Competing endogenous lncRNA 3 for miR-645 (CERNA3/CTA) is a human long non-coding RNA gene located on chromosome 8. It acts as a competing endogenous RNA (ceRNA), participating in post-transcriptional gene regulation by sponging microRNAs (such as miR-645), thus affecting the stability and translation of target mRNAs. Such lncRNAs are integral parts of ceRNA networks, which have been implicated in processes including cancer development, cell proliferation, immune response, and therapeutic resistance. While lncRNA-based ceRNA networks are promising therapeutic targets and biomarkers in oncology and other disease contexts, direct pharmacological targeting of CERNA3 has not been described. CERNA3 is referenced in major gene/protein databases with aliases including CTA, and it fits molecular classifications of lncRNA and ceRNA.
- Other names
- CERNA3CTA
02
Mechanism of action
Drugs affecting ceRNA networks may work by disrupting miRNA-lncRNA-mRNA interactions, potentially restoring or inhibiting specific gene regulatory circuits involved in disease progression
03
Biological functions
Regulation of gene expression post-transcriptionally by acting as an miRNA spongeParticipation in dynamic ceRNA networks that modulate mRNA stability and translationPotential involvement in cell proliferation, apoptosis, migration, immune response, and tumorigenesis where ceRNA mechanisms are relevant
04
Disease associations
Cancer (particularly mechanisms where ceRNA networks play a role, such as hepatocellular carcinoma or other malignancies)Other diseases modulated by ceRNA-mediated lncRNA-miRNA-mRNA networks, including possible roles in immune escape
05
Safety considerations
No explicit safety concerns are reported for targeting CERNA3; therapeutic challenges may include off-target effects and perturbation of complex ceRNA networks
06
Interacting drugs
Sorafenib indirectly interacts with lncRNA-mediated ceRNA networks in hepatocellular carcinoma, but no specific drugs directly target CERNA3 as of the current data
07
Biomarkers
Expression of specific ceRNAs/lncRNAs is explored as a biomarker for cancer progression, prognosis, or resistance to therapy, but CERNA3 itself is not currently a standard biomarker
Beyond the preview
Go deeper on Competing Endogenous LncRNA 3 for miR-645 (CERNA3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Competing Endogenous LncRNA 3 for miR-645 (CERNA3).